A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 13, 2023

Primary Completion Date

September 2, 2024

Study Completion Date

September 30, 2024

Conditions

Atopic Dermatitis

Interventions

DRUG

1.5% QLM3003

QLM3003 topical cream

DRUG

2% QLM3003

QLM3003 topical cream

DRUG

Vehicle (Placebo)

Vehicle topical cream

Trial Locations (2)

The First Hospital of China Medical University, Shenyang

Dermatology Hospital of Shandong First Medical University, Jinan

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06058000 - A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | Biotech Hunter | Biotech Hunter